Today’s announcement that Brilacidin has a selectivity index above 300 for CV19 is nothing short of OUTSTANDING. The SI rating is a proven data point of comparison that speaks to safety and efficacy that CAN NOT be ignored by the FDA and/or with the highest level of decision makers in the U.S. government.
- The combination of independent Lab Testing performed in government funded RBLs along with superior lab testing results IMO will secure government grant funding and expedite an approved CV-19 IND and human CV19 trials. Brilacidin’s safety and efficacy record in numerous FDA trials for other instances will be an additional proof point to move B-CV19 expeditiously through the approval process.
- The bar currently set for CV19 treatments is VERY low and Brilacidin will blow away current alternatives with superior efficacy by killing the CV19 virus on contact, prevent the viral replication and modulate the inflammatory response with anti-microbial and antibiotic properties.
- There is both a critical human need as well as a strong political driven influence that will expedite ANY effective CV19 therapeutics and treatments knowing that a safe and effective vaccine is very questionable in the short term and possibly even in the long term.
- Today’s share price “trading” highlights the desperation and resolve of the criminals responsible for ongoing IPIX SP manipulation. Today is simply another proof point that the criminal hedge fund led cabal that includes crooked MM’s and paid SMB posters will not be going away anytime soon. The criminals are doing anything and everything in their power to keep IPIX SP artificially compressed including spoofing volume with mirror trades and digging a continually larger hole with additional naked short selling (illegal vapor shares). Pardon the analogy but the criminals are the little Dutch boy with his finger in the dike. The next few “holes” for them will be peer review papers, an approved IND for B-CV19, initiation of B-CV19 human trials, success in CV-19 trials, FDA approved Emergency Use Authorization and final approval with a large procurement of Brilacidin by the US government. Each of these soon to be met milestones will provide increasingly more new investor demand that will eventually bust the dike wide open as the criminals run out of fingers. IPIX investors have a front row seat from higher ground. It will be an exciting next few weeks.
- The combination of independent Lab Testing performed in government funded RBLs along with superior lab testing results IMO will secure government grant funding and expedite an approved CV-19 IND and human CV19 trials. Brilacidin’s safety and efficacy record in numerous FDA trials for other instances will be an additional proof point to move B-CV19 expeditiously through the approval process.
- The bar currently set for CV19 treatments is VERY low and Brilacidin will blow away current alternatives with superior efficacy by killing the CV19 virus on contact, prevent the viral replication and modulate the inflammatory response with anti-microbial and antibiotic properties.
- There is both a critical human need as well as a strong political driven influence that will expedite ANY effective CV19 therapeutics and treatments knowing that a safe and effective vaccine is very questionable in the short term and possibly even in the long term.
- Today’s share price “trading” highlights the desperation and resolve of the criminals responsible for ongoing IPIX SP manipulation. Today is simply another proof point that the criminal hedge fund led cabal that includes crooked MM’s and paid SMB posters will not be going away anytime soon. The criminals are doing anything and everything in their power to keep IPIX SP artificially compressed including spoofing volume with mirror trades and digging a continually larger hole with additional naked short selling (illegal vapor shares). Pardon the analogy but the criminals are the little Dutch boy with his finger in the dike. The next few “holes” for them will be peer review papers, an approved IND for B-CV19, initiation of B-CV19 human trials, success in CV-19 trials, FDA approved Emergency Use Authorization and final approval with a large procurement of Brilacidin by the US government. Each of these soon to be met milestones will provide increasingly more new investor demand that will eventually bust the dike wide open as the criminals run out of fingers. IPIX investors have a front row seat from higher ground. It will be an exciting next few weeks.
14
